Connecticut Children's Medical Center
Connecticut Children's Medical Center sponsors 55 registered US clinical trials on ClinicalTrials.gov, 15 of them currently recruiting, and 35 completed. 6 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Glycogen Storage Disease Type Ia, with 2 trials.
Trial Pipeline
55 total, page 2 of 2
B2-Adrenergic Receptor Polymorphisms
NCT00279786
Reduction of Topical Anesthetic Time for Subcutaneous Port Access Using Ultrasound
NCT00126919
Reduction of Topical Anesthetic Onset Time Using Ultrasound
NCT00126932
Trial of Terbutaline for the Treatment of Status Asthmaticus in Children
NCT00124995
Pediatric Inflammatory Bowel Disease Collaborative Research Group Registry
NCT00833170
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 4 | 6 |
What the Pipeline for Connecticut Children's Medical Center Shows
According to the ClinicalTrials.gov registry, Connecticut Children's Medical Center is linked to 55 US clinical trials across every stage of research activity. Of those, 15 studies are currently recruiting, about 27% of the sponsor's indexed portfolio, and 35 are already marked complete, representing roughly 64% of the total.
The phase mix for Connecticut Children's Medical Center reports 6 late-stage studies (Phase 3 and Phase 4 combined) and 2 earlier-phase studies (Phase 1 and Phase 2).
The top therapeutic focus area indexed for Connecticut Children's Medical Center is Glycogen Storage Disease Type Ia with 2 linked trials, and 9 other condition areas appear in the top list above.
How to read these pipeline numbers
Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work, safety, dosing, and early signal detection, and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice, verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.